Evaluation of a Rapid and Accessible Reverse Transcription-Quantitative PCR Approach for SARS-CoV-2 Variant of Concern Identification

Priscilla S.-W. Yeung,a Hannah Wang,a Mamdouh Sibai,a Daniel Solis,a Fumiko Yamamoto,a Naomi Iwai,b Becky Jiang,b Nathan Hammond,d Bernadette Truong,b Selamawit Bihon,b Suzette Santos,b Marilyn Mar,b Claire Mai,c Kenji O. Mfuh,b Jacob A. Miller,d ChunHong Huang,a Malaya K. Sahoo,a James L. Zehnder,a Benjamin A. Pinsky,a,b,e

aDepartment of Pathology, Stanford University School of Medicine, Stanford, California, USA
bClinical Virology Laboratory, Stanford Health Care, Stanford, California, USA
cClinical Genomics Laboratory, Stanford Health Care, Stanford, California, USA
dDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA
eDivision of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, California, USA

Priscilla S.-W. Yeung and Hannah Wang contributed equally to this article. Author order was determined reverse alphabetically.

ABSTRACT The ability to distinguish between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants of concern (VOCs) is of ongoing interest due to differences in transmissibility, responses to vaccination, clinical prognosis, and therapy. Although detailed genetic characterization requires whole-genome sequencing (WGS), targeted nucleic acid amplification tests can serve a complementary role in clinical settings, as they are more rapid and accessible than sequencing in most laboratories. We designed and analytically validated a two-reaction multiplex reverse transcription-quantitative PCR (RT-qPCR) assay targeting spike protein mutations L452R, E484K, and N501Y in reaction 1 and del69–70, K417N, and T478K in reaction 2. This assay had 95 to 100% agreement with WGS for 502 upper respiratory tract swab samples collected between 26 April 2021 and 1 August 2021, consisting of 43 Alpha, 2 Beta, 20 Gamma, 378 Delta, and 59 non-VOC infections. Validation in a separate group of 230 WGS-confirmed Omicron variant samples collected in December 2021 and January 2022 demonstrated 100% agreement. This RT-qPCR-based approach can be implemented in clinical laboratories already performing SARS-CoV-2 nucleic acid amplification tests to assist in local epidemiological surveillance and clinical decision-making.

KEYWORDS COVID-19, Omicron, SARS-CoV-2, variant

S
since the original strain of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first discovered in late 2019, numerous new variants have been identified, including variants of concern (VOCs) Alpha (B.1.1.7 and sublineages), Beta (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2 and sublineages), and Omicron (B.1.1.529 and sublineages) (1). Importantly, these VOCs differ in their clinical prognosis, transmissibility, antibody susceptibility, and response to vaccination (2–22). Whole-genome sequencing (WGS) has played a critical role in identifying the emergence of these new variants (23–25), and millions of distinct sequences have been deposited in public repositories such as the Global Initiative on Sharing Avian Influenza Data (GISAID) database (26). However, WGS has a relatively long turnaround time, is labor-intensive, and requires instruments, bioinformatic support, and specially trained staff that may not be widely available to many clinical laboratories. Therefore, the development of reverse transcription-quantitative PCR (RT-qPCR) assays to presumptively type SARS-CoV-2 variants may be an important real-time complement to WGS epidemiological surveillance and may...
directly impact the clinical care of individual patients by informing selection of expensive and potentially difficult-to-source monoclonal antibody therapies (2, 7, 13–17, 20, 21, 27). It is important to note that such presumptive typing assays may provide atypical results for emerging strains due to mutations within primer and/or probe binding sites. Therefore, they must be intelligently designed, thoroughly validated, and interpreted carefully.

In this study, we report the design of a multiplex RT-qPCR assay that detects the del69–70, K417N, T478K, E484K, and N501Y mutations in SARS-CoV-2 spike protein and targets the wild-type 69 to 70 (wt69–70) sequence as an internal control. We further evaluate the performance of this assay in combination with our previously described RT-qPCR assay for the detection of L452R, E484K, and N501Y (28) and demonstrate the utility of this targeted mutational analysis to accurately distinguish among VOCs.

**MATERIALS AND METHODS**

**Assay design.** The spike protein mutations associated with each variant that are interrogated by the RT-qPCR assays are summarized in Fig. 1. In the first reaction (reaction 1), we utilized our previously described RT-qPCR assay to detect L452R, E484K, and N501Y mutations in the spike receptor binding domain (RBD) (28). The present study describes the combination of this assay with a second, newly designed reaction (reaction 2), which detects the deletion of amino acids 69 and 70 in the spike N-terminal domain (del69–70) as well as K417N and T478K mutations in the RBD. We use allele-specific RT-qPCRs with probe sequences designed to maximize the difference in annealing temperatures between mutant and wild-type sequences, allowing differential binding and amplification. The primer/probe sequences for each mutation site are summarized in Table 1, and the guidance for interpretation and reporting is described in Table 2. Additional details are provided in the supplemental material, including single-stranded DNA (ssDNA) sequences for analytical experiments (see Table S1 in the supplemental material), analytical validation data (see Table S2), and in silico analysis of primer and probe sequences (see Fig. S1).

**Clinical specimens.** The samples included in the initial phase of this study were upper respiratory tract swab specimens collected from patients as part of routine clinical care between 26 April 2021 and 1 August 2021. Testing was performed at the Stanford Clinical Virology Laboratory, which provides virological testing for all Stanford-affiliated hospitals and outpatient centers in the San Francisco Bay Area. These initial SARS-CoV-2 nucleic acid amplification tests (NAA Ts) prior to genotyping were conducted according to manufacturer and emergency authorization instructions, as described previously (28) and in the supplemental material. All samples that tested positive for SARS-CoV-2 RNA were subjected to genotyping. We then excluded samples that were initially tested by laboratory-based methods with cycle threshold (Cₜ) values of ≥35 or relative light unit (RLU) values of ≤1,100. We included all available samples that were initially tested at or near the point of care, because Cₜ data were not readily available.

---

**FIG 1** Summary of current WHO-designated VOC along with their expected spike mutations at sites targeted by this two-reaction multiplex SARS-CoV-2 RT-qPCR genotyping approach. These reactions are designed to detect the following mutations: del69–70, K417N, L452R, T478K, E484K, and N501Y. Shading indicates predicted versus empirical performance of this assay for the detection and differentiation of these VOCs. The predicted detection for the VOC Omicron is based on both the sequence at the target sites and known adjacent mutations in the probe binding site. *, Known limitation of the assay in differentiating VOC Beta from the VOI Mu; **, known limitation of the assay in differentiating VOC Gamma from the VOI Mu.
Any target with C\textsubscript{\textit{v}} value of >40 or abnormal/inconclusive amplification curves

Any scenarios not designated above

**TABLE 1** Reaction 2 primer and probe oligonucleotide sequences

| Name\(^a\) | Sequence (5\textsuperscript{\textprime}→3\textsuperscript{\textprime}) | Final conc (nM) |
|-----------|-------------------------------------------------|-----------------|
| **Primers** | | |
| del69–70\_FWD | CATTAATGGTAGGACAGGGTTA | 300 |
| del69–70\_REV | ACATTCACCTCAGGACTGTT | 300 |
| K417N\_FWD | GCACGCCGTAACATATCGT | 300 |
| K417N\_REV | CATTTCATTAGGGTAGGATGAC | 300 |
| T478K\_FWD | AGGGAGAGCATTAAACAT | 300 |
| T478K\_REV | AGGAGGCTATTCACACACT | 300 |
| **Probes** | | |
| del69–70\_MT\_HEX | HEX-TTGGTCCAGATAGCATG-BHQ1 | 50 |
| wt69–70\_WT\_CY3.5 | CY3.5-GTCCCCAGAGACATG-BHQ2 | 50 |
| K417N\_MT\_CY5 | CY5-ACATCGACATATTTCCAGT-BHQ2 | 50 |
| T478K\_MT\_FAM | FAM-ACCATACACAGTGTGCTAC-BHQ1 | 50 |

\(^a\)FWD, forward; REV, reverse; WT, wild-type; MT, mutant; CY3.5, cyanine 3.5; BHQ, black hole quencher.

\(^b\)Included as an internal amplification control for samples without the del69–70 mutation.

for real-time specimen triage for these samples. We also excluded follow-up specimens to eliminate patient-level duplicates. Subsequent validation of this assay for Omicron variant detection was conducted using a convenience set of 230 Omicron variant samples with available WGS data that were collected between 2 December 2021 and 5 January 2022. This study was conducted with Stanford University institutional review board approval (protocol 57519), and the requirement for individual consent was waived.

**WGS.** To validate the genotyping RT-qPCRs, we tested their performance against WGS for a subset of the samples in the initial cohort from 26 April 2021 to 1 August 2021 with C\textsubscript{\textit{v}} values of <30. Samples with non-dominant variant typing by RT-qPCR were prioritized for sequencing, with the remaining isolates chosen randomly to fill a sequencing run. WGS was conducted as described previously, using a laboratory-developed pipeline consisting of long-range PCR followed by fragmentation and then single-end 150-cycle sequencing using the MiSeq reagent kit v3 (Illumina, San Diego, CA) (28). Genomes were assembled via a custom assembly and bioinformatics pipeline using NCBI GenBank accession number NC_045512.2 as the reference. Whole-genome sequences with ≥75% genome coverage to a depth of at least 10 reads were accepted for interpretation. Mutation calling required a depth of at least 12 reads with a minimum variant frequency of 20%. PANGO lineage assignment was performed using the Pangolin Coronavirus Disease 2019 (COVID-19) Lineage Assigner

**TABLE 2** Interpretation and reporting of the two-reaction multiplex genotyping RT-qPCR results

| Reaction 1 results\(^a\) | Reaction 2 results | Action (see comments)\(^b\) |
|---------------------|---------------------|---------------------|
| N501WT (ROX/Cy3.5) | 69\_70WT (ROX/Cy3.5) | K417N (CY5) | Del69\_70 (HEX) |
| N501Y (FAM) | T478K (FAM) | |
| E484K (CY5) | K417N (HEX) | Del69\_70 (HEX) |
| L452R (HEX) | Action (see comments)\(^b\) |
| DTD ≤40 | NDET | NDET | DTD ≤40 | DTD ≤40 | NDET | Report as 1 |
| DTD ≤40 | NDET | NDET | DTD ≤40 | DTD ≤40 | NDET | Report as 1 |
| DTD ≤40 | NDET | NDET | DTD ≤40 | DTD ≤40 | NDET | Report as 1 |
| NDET | DTD ≤40 | DTD ≤40 | NDET | DTD ≤40 | NDET | Report as 2 |
| NDET | DTD ≤40 | DTD ≤40 | NDET | DTD ≤40 | NDET | Report as 2 |
| NDET | DTD ≤40 | DTD ≤40 | NDET | DTD ≤40 | NDET | Report as 4 |
| NDET | DTD ≤40 | DTD ≤40 | NDET | DTD ≤40 | NDET | Report as 5 |
| NDET | DTD ≤40 | DTD ≤40 | NDET | DTD ≤40 | NDET | Report as 5 |

Any target with C\textsubscript{\textit{v}} value of >40 or abnormal/inconclusive amplification curves

Any scenarios not designated above

\(^a\)DTD ≤40, detected with a C\textsubscript{\textit{v}} value of ≤40; NDET, not detected.

\(^b\)Result interpretation: 1. Probable VOC Delta; increased transmissibility; decreased susceptibility to bamlanivimab (LY-CoV555). 2. Possible VOC Beta versus VOI Mu; decreased susceptibility to bamlanivimab, etesevimab (LY-CoV016, JS016, CB6ETE), bamlanivimab plus etesevimab, casirivimab (REGN10933), and regdanvimab (CT-P59). 3. Possible VOC Gamma versus VOI Mu; decreased susceptibility to bamlanivimab, etesevimab, bamlanivimab plus etesevimab, casirivimab, and regdanvimab. 4. Probable VOC Alpha; decreased susceptibility to etesevimab. 5. Probable VOC Omicron; increased transmissibility; decreased susceptibility to bamlanivimab, etesevimab, bamlanivimab plus etesevimab, casirivimab, imdevimab (REGN10987), casirivimab plus imdevimab (REGN-COV2), cilgavimab (COV2-2130, AZD1061), tixagevimab (COV2-2196, AZD8895), cilgavimab plus tixagevimab, and regdanvimab; Decreased susceptibility to convalescent plasma. 6. Unable to interpret results due to low level of viral RNA. 7. Triage for medical director review (mutations uncommonly seen together, which could indicate possible mixed infection, contamination, or nonspecific amplification; analyze additional information, including previous results and curve shape; potential new variant or novel mutation in primer/probe sites causing dropout); consider sequencing if the level of viral RNA is sufficient. Interpretations regarding monoclonal antibody susceptibility and plasma susceptibility were based on data from the Stanford Coronavirus Antibody and Resistance Database (https://covdb.stanford.edu). Decreased susceptibility to monoclonal antibodies and convalescent plasma was defined as a >10-fold reduction in neutralization.
Running Pangolin v3.1.17, while Nextclade Web v1.13.1 and auspice.us v0.8.0 were used to perform phylogenetic placement (3, 29, 30). Both lineage and clade assignments were performed on 1 February 2022. WGS data were deposited in GISAID (see Table S3).

**Statistical analysis.** Positive percent agreement (PPA) and negative percent agreement (NPA) were reported with Clopper-Pearson score 95% binomial confidence intervals (CIs) using WGS as the reference method. Analyses were conducted using the R statistical software package. This study was reported in accordance with Standards for Reporting of Diagnostic Accuracy Studies (STARD) guidelines.

**RESULTS**

During the initial study period of 26 April 2021 to 1 August 2021, the Stanford Clinical Virology Laboratory received 102,158 specimens from 70,544 unique individuals. A total of 1,657 samples from unique individuals tested positive for SARS-CoV-2, of which 1,093 (66%) had genotyping RT-qPCR 1 and 2 performed and 502 (30.3%) had successful WGS performed (see Fig. S2 in the supplemental material). The lower limits of detection for the mutation site probes in reaction 2 were 14.8 copies/μL template for del69–70 (hexachlorofluorescein [HEX]), 16.4 copies/μL template for K417N (cyanine 5 [C5]), and 2.1 copies/μL template for T478K (5(6)-carboxyfluorescein [FAM]).

The median number of aligned reads for WGS was 485,870 (interquartile range [IQR], 289,363 to 655,481 reads), while the median genome coverage to a depth of at least 10 reads was 99.3% (IQR, 97.1 to 99.3%). Of note, reaction 1 was performed in near real time, while reaction 2 was performed retrospectively. Overall, this subset of sequenced samples had patient and testing characteristics that closely resembled those of the larger cohorts (see Table S4).

The assay yielded “unable to genotype” results for 152 of 1,093 samples (14%) due to lack of amplification of any target in either or both reactions. Assay failure occurred predominantly in samples that were originally tested at or near the point of care (119/341 samples [35%]), where all positive samples were triaged for genotyping without any filter. In contrast, assay failure occurred much less frequently in samples that were originally tested in the moderate-to-high-complexity virology laboratory (33/752 [4%]), where samples with lower viral RNA levels (CT values of ≥35) were not triaged for genotyping. In the group of 752 samples tested in the virology laboratory, 601 had known CT values. Among those 601 samples, 68 had CT values of >30, of which 11/68 (16%) failed amplification.

PPA and NPA values for the six individual mutations targeted by the genotyping RT-qPCRs, compared to WGS, were calculated for the 502 samples for which both RT-qPCR and WGS were performed (see Fig. S2). The number of samples that tested positive for each mutation reflects the natural prevalence of each mutation during that time period. For the combination of reactions 1 and 2, the PPA values for del69–70, L452R, T478K, E484K, and N501Y were 100% (Table 3). Across all six loci, only K417N had a false-negative result, resulting in a PPA of 96% (27/28 samples); in that sample, WGS showed a synonymous T-to-C mutation at position 1254 of the spike gene, corresponding to amino acid position 418, changing the codon from ATT to ATC. This single-base pair substitution likely decreased the annealing temperature, causing probe dropout and a false-negative result.

For the L452R target, there were 3 samples that tested positive for the L-to-R mutation but in fact had a L452R mutation, as determined by WGS. In both the E-to-K mutation (GAA to AAA) and the E-to-Q mutation (GAA to CAA), there was a single base substitution at the first position of the codon, resulting in nonspecific probe binding. These three samples had a distinct blunted amplification curve with high CT values.
TABLE 3 Comparison of RT-qPCR and WGS results for SARS-CoV-2 spike gene mutation detection in the initial cohort (n = 502)

| Spike mutation and RT-qPCR result | No. with positive WGS result | No. with negative WGS result | PPA (95% CI) (%) | NPA (95% CI) (%) |
|-----------------------------------|-----------------------------|-----------------------------|-----------------|-----------------|
| Del69–70                          |                             |                             |                 |                 |
| Positive                          | 43                          | 0                           | 100 (92–100)    | 100 (99–100)    |
| Negative                          | 0                           | 459                         |                 |                 |
| K417N                             |                             |                             |                 |                 |
| Positive                          | 27                          | 0                           | 96 (82–100)     | 100 (99–100)    |
| Negative                          | 1<sup>a</sup>              | 474                         |                 |                 |
| L452R                             |                             |                             |                 |                 |
| Positive                          | 403                         | 5<sup>b</sup>              | 100 (99–100)    | 95 (89–98)      |
| Negative                          | 0                           | 94                          |                 |                 |
| T478K                             |                             |                             |                 |                 |
| Positive                          | 379                         | 0                           | 100 (99–100)    | 100 (97–100)    |
| Negative                          | 0                           | 123                         |                 |                 |
| E484K                             |                             |                             |                 |                 |
| Positive                          | 35                          | 3<sup>c</sup>              | 100 (90–100)    | 99 (98–100)     |
| Negative                          | 0                           | 464                         |                 |                 |
| N501Y                             |                             |                             |                 |                 |
| Positive                          | 70                          | 0                           | 100 (95–100)    | 100 (99–100)    |
| Negative                          | 0                           | 432                         |                 |                 |

<sup>a</sup>False-negative RT-qPCR result due to a synonymous mutation at spike amino acid position 418 (codon ATT to ATC), causing probe dropout.

<sup>b</sup>False-negative WGS results due to insufficient read counts (<12 reads) at this codon. Manual review of the sequences revealed 3 to 9 mutant reads in each sample.

<sup>c</sup>These 3 samples were found by WGS to be positive for E484Q. While positive for the E484K target by RT-qPCR, these samples had a distinct blunted amplification curve associated with E484Q, as described previously (31).

associated with E484Q, as described previously (31). While this cross-reactivity is a limitation of the E484K probe design, the unusually shaped amplification curves were identified and flagged for medical director review as part of the assay interpretation protocol (Table 2). Presumptive typing for such cases would need to be deferred until WGS confirmation.

Of note, there was a subset of variant AY.2, involving 4 specimens in our cohort, that had a V70F mutation causing both del69–70 and wt69–70 probes not to bind. However, because this variant would have T478K and K417N detected, the wt69–70 signal was not needed as an amplification control. This subset of the AY.2 genotype is expected to be positive for L452R and N501 wild-type internal controls while negative for N501Y and E484K in reaction 1 and positive for K417N and T4748K while negative for del69–70 and wt69–70 internal controls in reaction 2. This scenario has been reflected in the clinical interpretation table (Table 2).

SARS-CoV-2-positive specimens collected starting on 2 December 2021 began to show an unusual combination of mutations, i.e., the presence of K417N and del69–70 only in reaction 2, with all targets, including the internal control N501, not detected in reaction 1. Based on in silico analysis, we determined that these cases likely represented the Omicron variant. While most Omicron variant strains possess del69–70, K417N, T478K, and N501Y mutations, they also have A67V, S477N, and Q498R mutations, which would be predicted to interfere with binding of the del69–70/wt69–70, T478K, and N501Y/N501 probes, respectively. Although the E484K probe demonstrated cross-reactivity with strains containing the E484Q mutation, as described above, the E484K probe did not detect the E484A mutation in the Omicron variant since it differed by ≥2 bases. The del69–70 probe likely was able to retain some degree of binding due to the wider melting temperature differential of a 6-nucleotide deletion, compared to
a point mutation. Therefore, we validated this assay for Omicron detection using a set of 230 SARS-CoV-2-positive samples confirmed to be Omicron by WGS. We found that the unique pattern of K417N and del69–70 in reaction 2, along with the failure to amplify any target, including the internal control, in reaction 1, was present in 230/230 (100% [95% CI, 98 to 100%]) Omicron samples tested. This pattern was not seen in any of the 1,093 non-Omicron samples previously genotyped.

We next predicted the World Health Organization (WHO) variant designation of samples using RT-qPCR results and correlated them with the PANGO lineage assignments based on WGS data (Table 4). Mapping the genotyping results for the cohort based on RT-qPCR mutation analysis onto the Nextclade phylogenetic tree demonstrated close correlation with their WHO variant designations (Fig. 2). Among the 732 clinical samples that were tested by both RT-qPCR and WGS, 43 samples (5.9%) were Alpha (B.1.1.7 or Q.3), 2 samples (0.3%) were Beta (B.1.351), 20 samples (2.7%) were Gamma (P.1 and sublineages), 378 samples (51.6%) were Delta (B.1.617.2 or AY sublineages), and 230 samples (31.4%) were Omicron (B.1.1.529 or BA sublineages). There were no RT-qPCR false-negative results in assigning samples to these lineages. In addition, 59 samples (8.1%) that were tested by WGS that did not correspond to a WHO VOC as of 2 February 2022. Within this subset, there were 4 samples that were erroneously assigned as Gamma and 1 that was assigned as Beta by RT-qPCR. By WGS, these samples were variant of interest (VOI) Mu (B.1.621 or BB.2). This variant shares mutations E484K and N501Y with both the Beta and Gamma variants. A subset of Mu also includes the K417N mutation, which is seen in the Beta variant. Thus, our PCR assay could not distinguish VOI Mu from VOCs Beta and Gamma. Our interpretation table information reflects this limitation (Table 2). The remaining 54 samples did not contain mutation patterns associated with VOCs by either RT-qPCR or WGS.

**DISCUSSION**

The ability to distinguish between SARS-CoV-2 VOCs is important for epidemiological surveillance and, in certain circumstances, the care of individual COVID-19 patients. In this study, we describe a two-reaction, multiplex RT-qPCR genotyping approach that examines the spike mutations del69–70, K417N, L452R, T478K, E484K, and N501Y. This targeted mutational analysis can be used to differentiate between the WHO VOCs Alpha (B.1.1.7 and sublineages), Beta (B.1.351), Gamma (P.1 and sublineages), Delta (B.1.617.2 and sublineages), and Omicron (B.1.1.529 and sublineages), as well as to identify samples that cannot be categorized as a known VOC or VOI. Because the first part of this approach, reaction 1, was described previously, this study focuses on reaction 2 and the integrated results of the two-reaction test (28). Overall, these reactions showed high levels of concordance with WGS, demonstrating PPA values of 96 to 100% and NPA values of 95 to 100% for all targeted mutations.

Several groups previously described similar approaches to SARS-CoV-2 variant determination by RT-qPCR and digital droplet RT-PCR, particularly for the spike del69–70, E484K, and N501Y mutations (32–39). Some of those assays included additional mutation sites that were not in our study, such as spike del144 or open reading frame 1a (ORF1a) Δ3675–3677 (32, 38). Those earlier assays, published prior to the rise of Delta, primarily targeted VOCs Alpha, Beta, and Gamma. They were then followed by a surge of reports on the detection of the Delta variant. Garson et al. utilized double-mismatch allele-specific RT-PCR at L452R and T478K to differentiate the Delta variant from other VOCs among 42 U.K. patient samples (40). Aoki et al. described an approach that combined nested PCR along with high-resolution melting analysis at the same mutations, which was validated in a small Japanese patient cohort (41). Barua et al. used a slightly different approach, taking advantage of the difference in melting temperature for a probe targeted to the Delta spike mutation T478K, compared to other variants, for a Delta-specific RT-fluorescence resonance energy transfer (FRET)-PCR assay (42). Another defining feature of VOC Delta is spike del156–157, which was the target of a Delta variant PCR test developed by Hamill et al. (43). To our knowledge, the two-reaction multiplex RT-qPCR
### TABLE 4 Comparison of RT-qPCR and WGS results for SARS-CoV-2 VOC detection ($n = 732$)

| WHO VOC and PANGO lineage by WGS | No. with RT-qPCR result indicating: | Alpha | Beta | Gamma | Delta | Omicron | Non-VOC | Total no. |
|---------------------------------|-------------------------------------|------|-----|-------|-------|---------|---------|-----------|
| All Alpha                       |                                     | 43   | -   | -     | -     | -       | -       | 43        |
| B.1.1.7                         |                                     | 37   | -   | -     | -     | -       | -       | 37        |
| Q.3                             |                                     | 6    | -   | -     | -     | -       | -       | 6         |
| All Beta                        |                                     | -    | 2   | -     | -     | -       | -       | 2         |
| B.1.351                         |                                     | -    | 2   | -     | -     | -       | -       | 2         |
| All Gamma                       |                                     | -    | -   | 20    | -     | -       | -       | 20        |
| P.1                             |                                     | -    | -   | 13    | -     | -       | -       | 13        |
| P.1.10                          |                                     | -    | -   | 5     | -     | -       | -       | 5         |
| P.1.17                          |                                     | -    | -   | 2     | -     | -       | -       | 2         |
| All Delta                       |                                     | -    | -   | -     | 378   | -       | -       | 378       |
| B.1.617.2                       |                                     | -    | -   | -     | 29    | -       | -       | 29        |
| AY.1                            |                                     | -    | -   | -     | 20    | -       | -       | 20        |
| AY.2                            |                                     | -    | -   | -     | 5     | -       | -       | 5         |
| AY.3                            |                                     | -    | -   | -     | 5     | -       | -       | 5         |
| AY.4                            |                                     | -    | -   | -     | 1     | -       | -       | 1         |
| AY.13                           |                                     | -    | -   | -     | 13    | -       | -       | 13        |
| AY.14                           |                                     | -    | -   | -     | 59    | -       | -       | 59        |
| AY.19                           |                                     | -    | -   | -     | 1     | -       | -       | 1         |
| AY.20                           |                                     | -    | -   | -     | 5     | -       | -       | 5         |
| AY.23                           |                                     | -    | -   | -     | 2     | -       | -       | 2         |
| AY.25                           |                                     | -    | -   | -     | 1     | -       | -       | 1         |
| AY.25.1                         |                                     | -    | -   | -     | 2      | -       | -       | 2         |
| AY.26                           |                                     | -    | -   | -     | 7     | -       | -       | 7         |
| AY.35                           |                                     | -    | -   | -     | 2     | -       | -       | 2         |
| AY.43                           |                                     | -    | -   | -     | 7     | -       | -       | 7         |
| AY.44                           |                                     | -    | -   | -     | 25    | -       | -       | 25        |
| AY.46.2                         |                                     | -    | -   | -     | 2     | -       | -       | 2         |
| AY.47                           |                                     | -    | -   | -     | 32    | -       | -       | 32        |
| AY.48                           |                                     | -    | -   | -     | 59    | -       | -       | 59        |
| AY.52                           |                                     | -    | -   | -     | 1     | -       | -       | 1         |
| AY.54                           |                                     | -    | -   | -     | 1     | -       | -       | 1         |
| AY.59                           |                                     | -    | -   | -     | 3     | -       | -       | 3         |
| AY.62                           |                                     | -    | -   | -     | 8     | -       | -       | 8         |
| AY.67                           |                                     | -    | -   | -     | 1     | -       | -       | 1         |
| AY.74                           |                                     | -    | -   | -     | 10    | -       | -       | 10        |
| AY.75                           |                                     | -    | -   | -     | 8     | -       | -       | 8         |
| AY.98.1                         |                                     | -    | -   | -     | 1     | -       | -       | 1         |
| AY.100                          |                                     | -    | -   | -     | 3     | -       | -       | 3         |
| AY.103                          |                                     | -    | -   | -     | 26    | -       | -       | 26        |
| AY.110                          |                                     | -    | -   | -     | 9     | -       | -       | 9         |
| AY.114                          |                                     | -    | -   | -     | 1     | -       | -       | 1         |
| AY.116.1                        |                                     | -    | -   | -     | 2     | -       | -       | 2         |
| AY.118                          |                                     | -    | -   | -     | 5     | -       | -       | 5         |
| AY.119                          |                                     | -    | -   | -     | 4     | -       | -       | 4         |
| AY.120.1                        |                                     | -    | -   | -     | 1     | -       | -       | 1         |
| AY.121                          |                                     | -    | -   | -     | 3     | -       | -       | 3         |
| AY.122                          |                                     | -    | -   | -     | 5     | -       | -       | 5         |
| AY.126                          |                                     | -    | -   | -     | 2     | -       | -       | 2         |
| All Omicron                     |                                     | -    | -   | -     | 230   | -       | -       | 230       |
| B.1.1.529/BA.1                  |                                     | -    | -   | -     | 123   | -       | -       | 123       |
| BA.1.1                         |                                     | -    | -   | -     | 107   | -       | -       | 107       |
| All non-VOC                     |                                     | -    | 1   | 4     | -     | -       | -       | 59        |
| A.2.5                           |                                     | -    | -   | -     | -     | -       | -       | 6         |
| B.1                             |                                     | -    | -   | -     | -     | -       | -       | 3         |
| B.1.1.318                       |                                     | -    | -   | -     | -     | -       | -       | 1         |
| B.1.1.519                       |                                     | -    | -   | -     | -     | -       | -       | 1         |

(Continued on next page)
The approach outlined in this study examining six different mutation sites is the most comprehensive variant genotyping test described that can identify Alpha, Beta, Gamma, Delta, and Omicron variants.

Multiplex RT-qPCR SARS-CoV-2 genotyping takes advantage of a commonly used molecular technique that can be implemented by laboratories using existing equipment, materials, and personnel. Because this assay is more accessible and has a shorter turnaround time than WGS, we envision it serving as a complement to sequencing. The genotyping RT-qPCR can provide more detailed and up-to-date epidemiological information by increasing the sample size of categorized variants in each geographic region and can be essential in tracking local outbreaks in areas without direct access to WGS. For individual patients, the turnaround time of several hours also allows the assay to directly impact clinical care. For example, VOCs show different susceptibilities to monoclonal antibody treatments, and variant reporting could include this information (Table 2) (2). Furthermore, current ongoing trials for small-molecule drugs and other treatments may yield more information about variant-specific treatment strategies.

TABLE 4 (Continued)

| WHO VOC and PANGO lineage by WGS | No. with RT-qPCR result indicating: | Alpha | Beta | Gamma | Delta | Omicron | Non-VOC | Total no. |
|----------------------------------|-------------------------------------|-------|------|-------|-------|---------|---------|----------|
| B.1.311                          | -                                  | -     | -    | -     | -     | 1       | 1       |
| B.1.427                          | -                                  | -     | -    | -     | -     | 3       | 3       |
| B.1.429                          | -                                  | -     | -    | -     | -     | 8       | 8       |
| B.1.526                          | -                                  | -     | -    | -     | -     | 10      | 10      |
| B.1.621<sup>a</sup>              | -                                  | 1     | 2    | -     | -     | -       | 3       |
| BB.2<sup>a</sup>                 | -                                  | -     | 2    | -     | -     | -       | 2       |
| B.1.627                          | -                                  | -     | -    | -     | -     | 1       | 1       |
| B.1.637                          | -                                  | -     | -    | -     | -     | 11      | 11      |
| XB                               | -                                  | -     | -    | -     | -     | 9       | 9       |
| All                             | 43                                 | 3     | 24   | 378   | 230   | 54      | 732     |

<sup>a</sup>VOI Mu with E484K and N501Y mutations and a subset with K417N, which overlaps with VOCs Beta and Gamma.

<sup>b</sup>Dashes indicate none detected.

approach outlined in this study examining six different mutation sites is the most comprehensive variant genotyping test described that can identify Alpha, Beta, Gamma, Delta, and Omicron variants.

Multiplex RT-qPCR SARS-CoV-2 genotyping takes advantage of a commonly used molecular technique that can be implemented by laboratories using existing equipment, materials, and personnel. Because this assay is more accessible and has a shorter turnaround time than WGS, we envision it serving as a complement to sequencing. The genotyping RT-qPCR can provide more detailed and up-to-date epidemiological information by increasing the sample size of categorized variants in each geographic region and can be essential in tracking local outbreaks in areas without direct access to WGS. For individual patients, the turnaround time of several hours also allows the assay to directly impact clinical care. For example, VOCs show different susceptibilities to monoclonal antibody treatments, and variant reporting could include this information (Table 2) (2). Furthermore, current ongoing trials for small-molecule drugs and other treatments may yield more information about variant-specific treatment strategies.

FIG 2 Nextclade phylogenetic tree of 3,097 SARS-CoV-2 genomes, including all 732 of the sequenced genomes from this study and 2,365 genomes from the Nextstrain global reference tree as of 2 February 2022. The 732 included genomes are colored according to RT-qPCR-genotyping-predicted variant type, with each circle representing a sequenced genome. Branch lengths correspond to nucleotide divergence. Sequenced genomes span the breadth of the reference tree. Annotation to the right of the tree indicates the variant type based on WGS. Variant determination by RT-qPCR matched that by WGS except for 1 sequence typed as Beta and 4 sequences typed as Gamma by RT-qPCR, which clustered with VOI Mu by WGS.
Sequencing is still needed, however, for the identification and confirmation of novel variants. This is evidenced by the 5 VOI Mu samples originally misidentified by RT-qPCR as Gamma and Beta. The two approaches are complementary in nature, and RT-qPCR genotyping can help triage or prioritize samples for sequencing. For example, prescreening by RT-qPCR can enrich for samples with atypical mutation patterns, leading to more efficient use of sequencing resources and, potentially, more rapid identification of new variants.

This RT-qPCR approach has several limitations, as evidenced by its assay failure rate of 14% across all tested samples in our initial cohort. Because multiplex RT-qPCRs involve a mixture of multiple sets of primers and probes, they are inherently less analytically sensitive than single-target assays. For samples with RNA concentrations near the lower limits of detection, freeze-thaw cycles could impact RNA stability and may not yield consistent results due to stochastic variation. This issue could be alleviated by implementing a Ct/RLU filter to genotype only samples most likely to yield interpretable results. Within our 1,093-sample cohort, the lower assay failure rate for samples tested in our clinical virology laboratory (4%), compared to near care settings (35%), is likely attributable to genotyping only specimens with higher viral RNA levels. Note, however, that, even with such filtering, mutation analysis by RT-qPCR remains more analytically sensitive than WGS. This study is also limited by the absence of VOC coinfections, such as coinfections with Delta and Omicron, although we anticipate that this RT-qPCR approach would be able to detect such cases. Future experiments will be required to confirm detection of VOC coinfections, including cases with different viral RNA levels and variant proportions.

Another limitation to this approach is the continuously evolving variant landscape, which may render such a targeted assay obsolete in a relatively short period of time. First, it is important to consider that the loss of expected internal control signal for the N501 and/or wt69–70 targets in known SARS-CoV-2 RNA-positive samples is itself useful information, analogous to the widely used spike gene target failure (36). Furthermore, the inclusion of multiple mutations in key residues that influence viral fitness and antibody escape helps guard against rapid obsolescence, as evidenced by the ability of the RT-qPCR approach to rapidly detect the emergence of the Omicron variant in our population, as well as all major variant replacements that occurred in 2021. Notably, this approach also revealed emerging community transmission of BA.2 in early 2022, with K417N and wt69–70 detected in reaction 2 and all targets, including N501, not detected in reaction 1. Nevertheless, flexibility and vigilance are required should redesign and revalidation be required as novel variants emerge.

In summary, we developed and validated a two-reaction multiplex RT-qPCR genotyping strategy that interrogates six clinically relevant mutations within the SARS-CoV-2 spike, namely, del69–70, K417N, L452R, T478K, E484K, and N501Y. This approach allows identification of WHO VOCs Alpha, Beta, Gamma, Delta, and Omicron, with excellent concordance to WGS results. Overall, this method complements WGS and is suitable for clinical decision-making, near-real-time variant surveillance, and the triage of samples for sequencing.

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.
SUPPLEMENTAL FILE 1, PDF file, 0.2 MB.

ACKNOWLEDGMENTS

We thank the Stanford Clinical Virology Laboratory staff members for their excellence and perseverance in caring for our community while facing the unique challenges of this pandemic. We additionally are grateful to the Stanford Protein and Nucleic Acid Facility for the synthesis of reagents on short notice.

REFERENCES

1. World Health Organization. 2022. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants. Accessed 28 February 2022.
2. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovskoy Pond SL, Fera D, Shafer RW. 2021. The biological and clinical significance of
SARS-CoV-2 Variant of Concern Genotyping

May 2022 Volume 60 Issue 5 10.1128/jcm.00178-22 11